Quick Answer
Kyverna Therapeutics, Inc. reported Net Income of -$161.31 million for fiscal year 2025.
Kyverna Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$161.31M | -26.5% |
| 2024 | -$127.48M | -111.2% |
| 2023 | -$60.37M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$36.79M | -6.7% | +12.6% |
| June 30, 2025 | -$42.08M | -46.1% | +5.7% |
| March 31, 2025 | -$44.63M | -67.2% | -29.4% |
| September 30, 2024 | -$34.49M | -123.0% | -19.8% |
| June 30, 2024 | -$28.80M | -120.0% | -7.9% |
| March 31, 2024 | -$26.69M | -139.5% | -72.6% |
| September 30, 2023 | -$15.46M | — | -18.1% |
| June 30, 2023 | -$13.09M | — | -17.5% |
- Kyverna Therapeutics, Inc. showed a decrease of -26.5% in Net Income compared to the prior fiscal year.
- Over the 2023–2025 period, Kyverna Therapeutics, Inc.’s net income has declined by 167.2% (from -$60.37 million to -$161.31 million).
- The most recent figure is from Kyverna Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: